Huntsman Cancer Institute (HCI) is pleased to announce the appointment of two of our colleagues as holders of prestigious endowed chairs at the University of Utah. Endowed chairs recognize academic distinction, promote excellence, and provide funds for cutting-edge research.
Cancer Research Posts
Dr. Martin McMahon and his research group study the genetic mutations that contribute to lung cancer. About 30% of lung cancers can now be treated based on the disease’s specific genetics. McMahon is hopeful that each subset of lung cancer will soon have its own precision treatment.
Kali Dale, a graduate research assistant at HCI, was selected to receive the National Cancer Institute Graduate Diversity Supplement.
Gurkan Mollaoglu, a graduate student in the Oliver Lab, received an F99 NCI Predoctoral to Postdoctoral Fellow Transition Award. This prestigious grant recognizes and supports outstanding graduate students who have demonstrated potential and interest in pursuing careers as independent cancer researchers.
“As a physician-scientist, the patients I’ve treated who haven’t made it are always in the back of my mind, moving my laboratory work forward,” says Michael Engel, MD, PhD. His research group studies the molecular details that lead to the development of childhood leukemias and then leverages that information to combat them.
Your body's metabolism is different from a cancer cell's metabolism. Researchers like graduate student Zhizhou Ye are studying how cancer cells rewire their metabolism to survive and grow. Understanding these processes in depth could lead to therapies that stop cancer's growth.
Volunteers are needed for a research study about quitting smoking. Participants will be compensated for their time and nicotine patches will be provided at no cost.
RNA modification is an area of cell biology few people have studied, and the idea of exploring the boundaries of the known world is what first attracted graduate student Archana Yerra to a career in science.
Our bodies fight cancer more than we really know, says Kenneth Grossmann, MD, PhD, a medical oncologist at Huntsman Cancer Institute (HCI) and assistant professor of dermatology at the University of Utah (U of U). And, he adds, advances in medicine can help the immune system fight cancer even better.
Governor Gary R. Herbert declared the week of June 19–24, 2017, as Cure Cancer Week in Utah. The proclamation comes during the week Huntsman Cancer Institute (HCI) at the University of Utah dedicates its major research expansion, the Primary Children’s and Families’ Cancer Research Center.
Huntsman Cancer Institute began in 1995 with an empty lot and a dream full of promise. Twenty-two years later, HCI is opening a major expansion that will double its research capacity.
For Brain Tumor Awareness Month, Randy Jensen, MD, PhD, wants you to know something: “There is a lot of hope for patients with brain tumors.”
Mary Beckerle, PhD, CEO and Director of Huntsman Cancer Institute (HCI) at the University of Utah testified before the United States House of Representatives Committee on Oversight and Government Reform. She spoke on the impact of federally-funded cancer research. Beckerle was invited to testify at this bipartisan hearing by Chairman Jason Chaffetz and Ranking Member Elijah Cummings.
Huntsman Cancer Institute (HCI) researcher Andrew Hahn, MD, received an award for his work in genitourinary cancers from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). The Conquer Cancer Foundation of ASCO Merit Award recognizes young researchers who have made a significant impact to their field of study and promotes clinical cancer research by giving recipients the chance to present their findings at conferences.
The 21st Century Cures Act, signed into law in December 2016, includes $4.8 billion to fund research and drug development. The law provided funds for a number of initiatives, including the “Cancer Moonshot” effort, which seeks to accelerate cancer research in the United States. Cancer researchers at HCI urge the community to continue to support biomedical research in order to develop safe and effective disease treatments.
On September 7, 2016, National Cancer Institute (NCI) Acting Director Douglas Lowy, MD, accepted the recommendations of the Cancer Moonshot Blue Ribbon Panel (BRP) on a set of scientific approaches to accelerate progress in cancer research. An overview of the report was published in the journal Science.
When Kiera Jorgensen was diagnosed with cancer at the age of 19, she fought not only sarcoma, but also a deadly mystery that had loomed over her family for generations. Now years out of treatment, Kiera has answers and is conducting research to help families like hers better understand a rare genetic mutation.
People who are overweight or obese are at higher risk for more cancers than previously thought, says a report published in the New England Journal of Medicine August 25, 2016. The International Agency for Research on Cancer (IARC) brought together a group of 21 researchers from around the world to look at more than 1,000 studies linking excess body fat and cancer. Neli Ulrich, PhD, senior director of Population Sciences at Huntsman Cancer Institute (HCI), was a member of the group. Ulrich is a cancer researcher who studies lifestyle and biologic factors in cancer prevention and cancer prognosis.
Congratulations to Theresa Werner, MD, Huntsman Cancer Institute (HCI) investigator and University of Utah assistant professor of medicine, who received a 2016 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). Dr. Werner serves as medical director of the HCI Clinical Trials Office and manages an extensive portfolio of cancer clinical studies.
Huntsman Cancer Institute (HCI) at the University of Utah participated in a national summit on the Cancer Moonshot initiative on June 29, 2016. The Cancer Moonshot Summits were organized at the request of Vice President Joe Biden, and more than 270 organizations hosted summits that brought together patients and survivors, researchers, physicians, advocates, philanthropists, and data and technology experts to brainstorm ways of speeding up progress in cancer prevention, diagnosis, treatment, and care over the next five years—and to ultimately end cancer as we know it.